Patterns of corticosteroid use among remdesivir and matched patients and associated clinical outcomes in hospitalized COVID-19 patients

References

• COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National institutes of health. [cited 2023 Jul 10]. Available from: https://www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• Ministarstvo zdravstva Republike Hrvatske. Smjernice za liječenje oboljelih od COVID-19, verzija 8 od 17. listopada 2022. 2022.
   Google Scholar
• Ministarstvo zdravstva Republike Hrvatske. Smjernice za liječenje oboljelih od COVID-19, verzija 1 od 8. rujna 2020. 2020.
   Google Scholar
• COVID-19 rapid guideline: managing COVID-19. NICE Guideline [NG191]. [updated 2021 Mar 23; cited 2023 Jun 22].
   Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021 Feb 25;384(8);693–704. PubMed PMID: 32678530; PubMed Central PMCID: PMCPMC7383595. eng. doi: 10.1056/NEJMoa2021436
   PubMed Web of Science ®Google Scholar
• Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020 Oct 6;324(13):1307–1316. PubMed PMID: 32876695; PubMed Central PMCID: PMCPMC7489411. eng. doi: 10.1001/jama.2020.17021
   PubMed Web of Science ®Google Scholar
• Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial. JAMA. 2021 Nov 9;326(18);1807–1817. PubMed PMID: 34673895; PubMed Central PMCID: PMCPMC8532039. eng. doi: 10.1001/jama.2021.18295
   PubMed Web of Science ®Google Scholar
• Bouadma L, Mekontso-Dessap A, Burdet C, et al. High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute hypoxemic respiratory failure: the COVIDICUS randomized clinical trial. JAMA Intern Med. 2022 Sep 1;182(9);906–916. PubMed PMID: 35788622; PubMed Central PMCID: PMCPMC9449796. eng. doi: 10.1001/jamainternmed.2022.2168
   PubMed Web of Science ®Google Scholar
• Granholm A, Munch MW, Myatra SN, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive care Med. 2022 Jan;48(1):45–55. PubMed PMID: 34757439; PubMed Central PMCID: PMCPMC8579417. eng. doi: 10.1007/s00134-021-06573-1
   PubMed Web of Science ®Google Scholar
• Tan RSJ, Ng KT, Xin CE, et al. High-dose versus low-dose corticosteroids in COVID-19 patients: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2022 Sep;36(9):3576–3586. PubMed PMID: 35715291; PubMed Central PMCID: PMCPMC9101704. eng. doi: 10.1053/j.jvca.2022.05.011
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - final report. N Engl J Med. 2020 Nov 5;383(19);1813–1826. PubMed PMID: 32445440; PubMed Central PMCID: PMCPMC7262788. eng. doi: 10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 5;8(8):Cd014962. PubMed PMID: 34350582; PubMed Central PMCID: PMCPMC8406992. eng. doi: 10.1002/14651858.Cd014962
   PubMed Web of Science ®Google Scholar
• Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022 Feb 22;194(7):E242–e251. PubMed PMID: 35045989; PubMed Central PMCID: PMCPMC8863204. eng. doi: 10.1503/cmaj.211698
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Henao Restrepo AM, et al. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399(10339):1941–1953. PubMed PMID: 35512728; PubMed Central PMCID: PMCPMC9060606. eng. doi: 10.1016/s0140-6736(22)00519-0
   PubMed Web of Science ®Google Scholar
• Lucijanić M, Bušić N, Bistrović P, et al. Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry. Croat Med J. 2022 Dec 31;63(6):536–543. PubMed PMID: 36597565; PubMed Central PMCID: PMCPMC9837722. eng. doi: 10.3325/cmj.2022.63.536
   PubMed Web of Science ®Google Scholar
• Garibaldi BT, Wang K, Robinson ML, et al. Real-world effectiveness of remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): a retrospective, multicenter comparative effectiveness study. Clin Infect Dis. 2022 Aug 24;75(1):e516–e524. PubMed PMID: 34910128; PubMed Central PMCID: PMCPMC8754724. eng. doi: 10.1093/cid/ciab1035
   PubMed Web of Science ®Google Scholar
• Diaz GA, Christensen AB, Pusch T, et al. Remdesivir and mortality in patients with coronavirus disease 2019. Clin Infect Dis. 2022 May 30;74(10):1812–1820. PubMed PMID: 34409431; PubMed Central PMCID: PMCPMC9155603. eng. doi: 10.1093/cid/ciab698
   PubMed Web of Science ®Google Scholar
• World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. Geneva: World Health Organization. Contract No.: WHO/2019-nCoV/clinical/2020.5.2020. 2020.
   Google Scholar
• Papic I, Bistrovic P, Cikara T, et al. Corticosteroid dosing level, incidence and profile of bacterial blood stream infections in hospitalized COVID-19 patients. Viruses. 2024 Jan 5;16(1):86. PubMed PMID: 38257786; PubMed Central PMCID: PMCPMC10820464. eng. doi: 10.3390/v16010086
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Papic I, Ortner Hadziabdic M. Duration of corticosteroid treatment in hospitalized COVID-19 patients, less is more. Korean J Intern Med. 2024 Feb 6. PubMed PMID: 38317269; eng. doi: 10.3904/kjim.2023.450
   PubMed Web of Science ®Google Scholar
• Padilla S, Polotskaya K, Fernández M, et al. Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation. J Antimicrob Chemother. 2022 Jul 28;77(8):2257–2264. PubMed PMID: 35534369; eng. doi: 10.1093/jac/dkac144
   PubMed Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020 Sep 15;324(11):1048–1057. PubMed PMID: 32821939; PubMed Central PMCID: PMCPMC7442954. eng. doi: 10.1001/jama.2020.16349
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022 Jan 27;386(4):305–315. PubMed PMID: 34937145; PubMed Central PMCID: PMCPMC8757570. eng. doi: 10.1056/NEJMoa2116846
   PubMed Web of Science ®Google Scholar
• Lahmer T, Erber J, Schmid RM, et al. SARS-CoV-2 viral load dynamics in immunocompromised critically ill patients on remdesivir treatment. Multidiscip Respir Med. 2022 Jan 12;17:825. PubMed PMID: 35646346; PubMed Central PMCID: PMCPMC9134301. eng. doi: 10.4081/mrm.2022.825
   PubMed Web of Science ®Google Scholar
• Bistrovic P, Manola S, Lucijanic M. Bradycardia during remdesivir treatment might be associated with improved survival in patients with COVID-19: a retrospective cohort study on 473 patients from a tertiary centre. Postgrad Med J. 2022 Jul;98(1161):501–502. PubMed PMID: 34876485; eng. doi: 10.1136/postgradmedj-2021-141079
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Cikara T, Bistrovic P, et al. Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis. J Infect. 2022 Aug;85(2):174–211. PubMed PMID: 35513188; PubMed Central PMCID: PMCPMC9060712. eng. doi: 10.1016/j.jinf.2022.04.045
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Bistrovic P, Jordan A, et al. Remdesivir use in severe and critical COVID-19 patients might be associated with lower incidence of arterial thrombotic events. Am J Emerg Med. 2023 May 10;70:41–45. PubMed PMID: 37201450; PubMed Central PMCID: PMCPMC10170894. eng doi: 10.1016/j.ajem.2023.05.007
   PubMed Web of Science ®Google Scholar
• Bistrovic P, Manola S, Papic I, et al. Atrial fibrillation in COVID-19 patients receiving remdesivir, matched case-control analysis. Am J Emerg Med. 2022 Sep;59:182–183. PubMed PMID: 35577624; PubMed Central PMCID: PMCPMC9085444. eng. doi: 10.1016/j.ajem.2022.04.051
   PubMed Web of Science ®Google Scholar
• Zhang W, Qin C, Fei Y, et al. Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: an update. Clin Immunol. 2022 Jun;239:109022. PubMed PMID: 35477027; PubMed Central PMCID: PMCPMC9040414. eng. doi: 10.1016/j.clim.2022.109022
   PubMed Web of Science ®Google Scholar